个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Landscape of somatic alterations in large-scale solid tumors from an Asian population

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Liqun Wu[1] ; Herui Yao[2] ; Hui Chen[3] ; Aodi Wang[3] ; Kun Guo[4] ; Wenli Gou[5] ; Yanfei Yu[3] ; Xiang Li[3] ; Ming Yao[3] ; Shaohua Yuan[3] ; Fei Pang[3] ; Jinwei Hu[3] ; Lijuan Chen[3] ; Wenjin Liu[3] ; Jicheng Yao[3] ; Shuirong Zhang[3] ; Xiaowei Dong[3] ; Weifeng Wang[3] ; Jing Hu[6] ; Qi Ling [7] ; Songming Ding[8] ; Yan Wei[9] ; Qiang Li[10] ; Weichun Cao[11] ; Shuang Wang[12] ; Yang Di[13] ; Feiling Feng[14] ; Gang Zhao[15] ; Jian Zhang[16] ; Ling Huang[17] ; Jia Xu[18] ; Wangjun Yan[19] ; Zhongsheng Tong[20] ; Da Jiang[21] ; Tao Ji [22] ; Qiao Li[23] ; Ling Xu[24] ; Huiying He [25] ; Liang Shang[26] ; Jin Liu[27] ; Kefeng Wang[28] ; Duoguang Wu[28] ; Jingnan Shen [29] ; Ye Liu[30] ; Ting Zhang[31] ; Chaojie Liang[32] ; Yusheng Wang[33] ; Yanhong Shang[34] ; Jianji Guo[35] ; Guanbiao Liang[35] ; Shifeng Xu[36] ; Junfeng Liu[37] ; Kai Wang[3] ; Minghui Wang[38] ;
机构： [1]Department of Hepatobiliary Surgery, Affiliated Hospital of Qingdao University, Qingdao, China [2]Guangdong Provincial Key Laboratory ofMalignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Breast Tumor Center and Phase I Clinical Trial Center, SunYat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China [3]Shanghai OrigiMed Co., Ltd, Shanghai, China [4]Liver Cancer Institute,Zhongshan Hospital, Fudan University, Shanghai, China [5]Department of Obstetrics and Gynecology, First Affiliated Hospital of Xi’an Jiao TongUniversity, Xi’an, China [6]Department of Medical Oncology, The First People’s Hospital of Yunnan Province, Kunming, China [7]Department ofSurgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China [8]Department of Hepatobiliary and PancreaticSurgery, Shu Lan (Hangzhou) Hospital, Hangzhou, China [9]Department of Oncology, Guigang City People’s Hospital, The Eighth AffiliatedHospital of Guangxi Medical University, Guigang, China [10]Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan MedicalUniversity, Nanchong, China [11]Department of Gynecologic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School ofMedicine, Central South University, Changsha, China [12]Department of Pathology, School of Basic Medical Sciences, Southern Medical University,Guangzhou, China [13]Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China [14]Department of Biliary Surgery,Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China [15]Department of Pathology, Tianjin Medical University Cancer Institute andHospital, Tianjin, China [16]Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science andTechnology, Wuhan, China [17]Department of Gastrointestinal Oncology, Huifuxi Branch of Guangdong Provincial People’s Hospital,Guangzhou, China [18]Department of Emergency, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China [19]Department ofMusculoskeletal Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China [20]Department of Breast Oncology, Tianjin MedicalUniversity Cancer Institute and Hospital, Tianjin, China [21]Department of Oncology, Fourth Hospital of Hebei Medical University,Shijiazhuang, China [22]Musculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, People’s Hospital, Peking University,Beijing, China [23]National Cancer Center/ Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and PekingUnion Medical College, Beijing, China [24]Breast Disease Center, Peking University First Hospital, Beijing, China [25]Department of Pathology,School of Basic Medical Sciences, Third Hospital, Peking University, Beijing, China [26]Department of Gastrointestinal Surgery, Shandong ProvincialHospital Affiliated to Shandong University, Jinan, China [27]Department of Gastroenterology, Shandong Provincial Hospital Affiliated to ShandongUniversity, Jinan, China [28]Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China [29]Department of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China [30]Department of Pathology, TheFifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China [31]Department of Bone Marrow, The First Affiliated Hospital, College of Medicine,Zhejiang University, Hangzhou, China [32]Department of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, China [33]Department of Digestive, Shanxi Provincial Cancer Hospital, Taiyuan, China [34]Department of Medical Oncology, The Affiliated Hospital, HebeiUniversity, Baoding, China [35]Department of Thoracic Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China [36]Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China [37]Department of ThoracicSurgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [38]Guangdong Provincial Key Laboratory of Malignant TumorEpigenetics and Gene Regulation, Department of Thoracic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120Guangzhou, China
出处：
DOI： 10.1038/s41467-022-31780-9
ISSN：

摘要：
Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.© 2022. The Author(s).

基金：
National Natural Science Foundation of China (No. 81872492, 81871886, 81572355), Shanghai Pujiang Program (No. 15PJD007), Natural Science Foundation of Guangdong Province (No. 2017A030313474), Guangdong Science and Technology Department (No. 2017A050501015, 2017B030314026), and Key Task Project of Tianjin Health and Family Planning Commission (No. 16KG128). The study was supported in part by the Wu Jie Ping Medical Foundation program (No. 320. 6750. 17).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
最新[2023]版：
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
JCR分区：
出版当年[2022]版：
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Hepatobiliary Surgery, Affiliated Hospital of Qingdao University, Qingdao, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Liqun Wu,Herui Yao,Hui Chen,et al.Landscape of somatic alterations in large-scale solid tumors from an Asian population[J].NATURE COMMUNICATIONS.2022,13(1):doi:10.1038/s41467-022-31780-9.
APA：
Liqun Wu,Herui Yao,Hui Chen,Aodi Wang,Kun Guo...&Minghui Wang.(2022).Landscape of somatic alterations in large-scale solid tumors from an Asian population.NATURE COMMUNICATIONS,13,(1)
MLA：
Liqun Wu,et al."Landscape of somatic alterations in large-scale solid tumors from an Asian population".NATURE COMMUNICATIONS 13..1(2022)

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号